Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2352W HIGH $6.43
Volume
699.69 K
Value Traded
7.85 M
Short % Float
19.29%
Days to Cover
10.4
-9.11%Week
-30.39%1 Month
-45.11%3 Month
-50.44%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
108.21 M
EPS (TTM)
-0.02
P/E Ratio
-
Ent. Value
83.07 M
Total Shares
48.20 M
Float Shares
39.17 M
Insiders
18.73%
Institutions
53.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LFMD Catalyst Timeline
Dated clinical, regulatory and corporate events for LifeMD, Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How LFMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
LifeMD, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LFMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kavthekar AtulOfficer (Chief Financial Officer) | Grant/Award | 337,500 337,500 held | $0.00 | 05/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LFMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LFMD for Q2 2026. | ||||
LFMD Institutional Ownership Trends
LFMD Short Interest
Shares sold short, counted twice a month.
19.29%
Short % of Float
of tradable shares sold short
7.6M
Shares Sold Short
+2.2% vs prior count
10.4 Very high
Days to Cover
trading days of normal volume to buy every short share back
729.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LFMD ranks across every disease it competes in
Competitive Position is a premium feature
See how LFMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLFMD News
-LFMD
Oct 20, 2026▼ -0.2%today
LifeMD to Report Third Quarter 2026 Financial Results on November 9
LifeMD, Inc. will report its financial results for Q3 2026 on November 9, 2026. The results will cover the three and nine months ended September 30, 2026. A conference call is scheduled for 8:30 a.m. Eastern time on the same day.
Read more →-LFMD
Sep 22, 2026▼ -7.6%on this news
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD, Inc. has declared a quarterly cash dividend of $0.5546875 per share on its Series A Cumulative Perpetual Preferred Stock. This dividend will be paid on October 15, 2026, to shareholders on record by October 2, 2026. The announcement highlights LifeMD's ongoing commitment to providing value to its investors.
Read more →-LFMD
Sep 15, 2026AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD
AT&T has partnered with LifeMD to provide eligible wireless and fiber customers with complimentary access to a virtual healthcare platform. This initiative allows customers to benefit from a $228 annual membership fee waiver, enabling them to connect with healthcare providers for various health needs. The service aims to enhance healthcare accessibility and convenience for millions of Americans.
Read more →-LFMD
Aug 5, 2026▼ -7.6%on this news
LifeMD Reports Second Quarter 2026 Results
LifeMD reported its second quarter 2026 results, achieving revenues of $47.3 million, which fell within the company's guidance range. The company noted a significant transition from compounded to branded GLP-1 therapies, with gross margins improving to 89%. Despite an adjusted EBITDA loss of $3.5 million, LifeMD expects to return to profitability in the second half of 2026, driven by growth in active subscribers and strategic partnerships.
Read more →-LFMD
Jul 24, 2026LifeMD to Report Second Quarter 2026 Financial Results on August 5
LifeMD, Inc. will report its financial results for Q2 2026 on August 5, 2026, after market close. The company will also host a conference call at 4:30 p.m. ET to discuss these results. LifeMD specializes in virtual primary care services and has a comprehensive digital care platform.
Read more →-LFMD
Jun 22, 2026▼ -9.3%on this news
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
LifeMD has announced a strategic collaboration with Antares Pharma to launch a self-pay program for XYOSTED, a testosterone injection. Set to begin in July 2026, the program will be available in 37 states and aims to enhance access to treatment for hypogonadism. The initiative includes consumer education and a streamlined telehealth process for patients.
Read more →-LFMD
May 15, 2026LifeMD to Participate in Upcoming Investor Conferences
LifeMD, Inc. will participate in two upcoming investor conferences: the LD Micro Invitational XVI Conference and the B. Riley Securities 26th Annual Investor Conference. Management will present at both events and is available for one-on-one meetings with investors. This engagement reflects LifeMD's strategy to enhance investor relations and showcase its virtual primary care services.
Read more →-LFMD
May 7, 2026▼ -14.8%on this news
LifeMD Reports First Quarter 2026 Results
LifeMD, Inc. reported strong financial results for Q1 2026, with a record addition of over 42,000 telehealth subscribers, bringing the total to over 365,000. The company achieved revenue of $50.2 million, surpassing its guidance. Management expressed optimism about future growth driven by strategic partnerships and new product launches in health services.
Read more →-LFMD
Apr 27, 2026LifeMD to Report First Quarter 2026 Financial Results on May 6
LifeMD, Inc. (Nasdaq: LFMD) will report its financial results for Q1 2026 on May 6, 2026, after U.S. market close. A conference call will follow at 4:30 p.m. Eastern time. LifeMD specializes in virtual primary care, providing telemedicine and access to various health services.
Read more →-LFMD
Mar 16, 2026▲ +10.6%on this news
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
LifeMD, Inc. has announced the appointment of Atul Kavthekar as Chief Financial Officer as part of its leadership expansion aimed at supporting growth. Kavthekar, a seasoned executive with nearly 30 years of experience in healthcare finance, will focus on strengthening the company’s financial strategy and operational infrastructure. Additionally, Chris Pisano has been appointed as Chief Marketing Officer, and Jessica Friedeman will take on the role of Chief Business Officer. These appointments reflect LifeMD's commitment to innovation and AI-driven healthcare delivery.
Read more →-LFMD
Mar 9, 2026LifeMD Reports Fourth Quarter and Full Year 2025 Results
LifeMD, Inc. reported strong financial results for the fourth quarter and full year 2025, with a revenue increase of 25% year-over-year to $194.1 million and adjusted EBITDA surging 309% to $15.3 million. The company successfully launched oral Wegovy, achieving notable patient sign-ups in weight management. Despite exiting with a solid cash position and no debt, LifeMD anticipates a short-term EBITDA loss in Q1 2026 due to strategic investments in patient acquisition. Overall, the company remains optimistic about future growth opportunities in the telehealth sector.
Read more →-LFMD
Feb 23, 2026▼ -6.4%on this news
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
LifeMD, Inc. will report its financial results for Q4 2025 on March 9, 2026, after market close. The company will also host a conference call at 4:30 p.m. Eastern time to discuss these results. LifeMD specializes in virtual primary care and offers various telemedicine services.
Read more →-LFMD
Jan 6, 2026▲ +7.9%on this news
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
LifeMD has announced the closing of a $50 million revolving credit facility with Citizens Bank, which features a maturity date of January 2, 2029. The facility provides $30 million of committed availability and an additional accordion option of up to $20 million. CFO Marc Benathen expressed confidence in the company's financial health, stating that the existing cash flow is sufficient for growth initiatives. The facility is competitively priced and offers significant financial flexibility for potential corporate development.
Read more →-LFMD
Jan 5, 2026▲ +12%on this newsshared move
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
LifeMD has expanded its collaboration with Novo Nordisk to offer the newly FDA-approved Wegovy® pill, the first oral GLP-1 therapy for chronic weight management. This partnership allows eligible patients to access the medication through LifeMD's telehealth platform at competitive prices. The initiative aims to enhance patient access to effective obesity treatments and streamline the healthcare experience.
Read more →-LFMD
Nov 17, 2025LifeMD Reports Third Quarter 2025 Results
LifeMD, a provider of virtual primary care services, reported its third-quarter 2025 results, showing a revenue increase of 13% year-over-year, totaling $60.2 million. The company has successfully improved its adjusted EBITDA by 20%, reaching $5.1 million, and reported growth in telehealth revenue at 18%. However, challenges in the weight management market and a net loss of $4.6 million were noted. The firm also divested its majority stake in WorkSimpli and is positioned to expand its telehealth and pharmacy services significantly in the coming year.
Read more →-LFMD
Nov 5, 2025Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
LifeMD, Inc. has announced the rescheduling of its third quarter 2025 earnings release to November 17, 2025, due to corrections in revenue recognition from previous periods. The adjustments, totaling approximately $4.6 million, are not expected to materially impact the company's cash flow. The company also plans to file a Form 12b-25 informing the SEC of the late filing. Despite the errors, LifeMD assures that the revisions will not significantly alter revenue results compared to prior guidance.
Read more →-LFMD
Nov 4, 2025▼ -5.6%on this newsshared move
Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
LifeMD, Inc. (Nasdaq: LFMD) has divested its majority ownership interest in WorkSimpli Software LLC for approximately $65 million, indicating a strategic shift towards focusing on virtual healthcare services and pharmacy offerings. The transaction, which closed on November 4, 2025, provided LifeMD with approximately $22 million in cash at closing, with potential for an additional $28 million based on WorkSimpli achieving future targets. This move is seen as a key milestone for LifeMD, allowing it to concentrate on expanding its core virtual care technologies and diversifying into new medical areas, while WorkSimpli enters a new phase of independence and growth.
Read more →About LifeMD, Inc. Common Stock
Headquarters236 FIFTH AVENUE, NEW YORK, NY, 10001
BIOPHARMAWATCH ELITE PLUS
Trade the next LFMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime